GMABGenmabRunning, no new patients
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
B-Cell Non-Hodgkin Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 49 (final count)
- Started
- Mar 10, 2022
- Main results expected
- Oct 2027
- Fully finished
- Oct 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1 Part 2 [(3L+) R/R DLBCL]: Best Overall Response (BOR)
Measured over: Up to Approximately 5 Years
Cohort 1 Part 1, Cohort 2, and Cohort 3: Number of Incidence of Dose-Limiting Toxicities (DLT)
Measured over: Up to Approximately 5 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05201248 · record last updated 2026-11-04 · checked 2026-11-09 15:42 UTC